<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04110782</url>
  </required_header>
  <id_info>
    <org_study_id>MP2018SAP</org_study_id>
    <nct_id>NCT04110782</nct_id>
  </id_info>
  <brief_title>Radical Prostatectomy and External Beam Radiotherapy in mCRPC With 223Radium-dicloride (RaProRad)</brief_title>
  <acronym>RaProRad</acronym>
  <official_title>Evaluation of Previeus Radical Prostatectomy and/or External Beam Radiotherapy as Protective Factors in mCRPC Patients Treated With 223Radium-dicloride and Correlation With Overall Survival: an Italian Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Policlinico Umberto I</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi di Bari Aldo Moro</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Palermo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Bologna</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Università degli Studi di Sassari</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ospedale Civile Spirito Santo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Policlinico Umberto I</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators provided a multicenter analysis aiming to investigate, in a clinical
      practice setting, the prognostic relevance of previous primary radical prostatectomy (RP) or
      external beam radiotherapy (RT) in terms of Overall Survival as opposed to patients with no
      primary treatment performed, in a cohort of patients enrolled in 223-Ra treatment for mCRPC.
      223-Ra has been administered from investigators according to the current label authorization
      and all patients underwent 223-Ra treatment, until disease progression or unacceptable
      toxicity.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2015</start_date>
  <completion_date type="Anticipated">January 2020</completion_date>
  <primary_completion_date type="Actual">June 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of overal survivall</measure>
    <time_frame>From date of first 223Ra administration until the date of death from any cause or the date of the first documented progression disease, assessed up to 48 months</time_frame>
    <description>The survival function, possibly stratified by categorical covariates of interest, was computed using the Kaplan-Meier product-limit estimator.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">400</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>Radium223</arm_group_label>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Radium223</intervention_name>
    <description>55 kBq/ Kg</description>
    <arm_group_label>Radium223</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        mCRPC patients admitt to Radium223 Therapy
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  histological confirmation of prostatic adenocarcinoma, at least two symptomatic bone
             secondary lesions detected by bone scan and no known visceral metastases, except for
             malignant lymphadenopathy with less than 3 cm in the short axis diameter

        Exclusion Criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) score &gt;2 and
             inadequate hematological, hepatic and renal function
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Prostate cancer</gender_description>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giuseppe De Vincentis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sapienza University of Rome</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giuseppe De Vincentis, MD, PhD</last_name>
    <phone>00390649978596</phone>
    <email>giuseppe.devincentis@uniroma1.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>VIVIANA FRANTELLIZZI, MD</last_name>
    <phone>00390649978573</phone>
    <email>viviana.frantellizzi@uniroma1.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Policlinico Umberto I</name>
      <address>
        <city>Rome</city>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giuseppe De Vincentis, MD, PhD</last_name>
      <phone>00390649978596</phone>
      <email>giuseppe.devincentis@uniroma1.it</email>
    </contact>
    <contact_backup>
      <last_name>VIVIANA FRANTELLIZZI, MD</last_name>
      <phone>00390649978573</phone>
      <email>viviana.frantellizzi@uniroma1.it</email>
    </contact_backup>
    <investigator>
      <last_name>Viviana Frantellizzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Parker C, Nilsson S, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, Bottomley D, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Coleman R, Vogelzang NJ, O'Bryan-Tear CG, Staudacher K, Garcia-Vargas J, Shan M, Bruland ØS, Sartor O; ALSYMPCA Investigators. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med. 2013 Jul 18;369(3):213-23. doi: 10.1056/NEJMoa1213755.</citation>
    <PMID>23863050</PMID>
  </reference>
  <reference>
    <citation>Parker CC, Coleman RE, Sartor O, Vogelzang NJ, Bottomley D, Heinrich D, Helle SI, O'Sullivan JM, Fosså SD, Chodacki A, Wiechno P, Logue J, Seke M, Widmark A, Johannessen DC, Hoskin P, James ND, Solberg A, Syndikus I, Kliment J, Wedel S, Boehmer S, Dall'Oglio M, Franzén L, Bruland ØS, Petrenciuc O, Staudacher K, Li R, Nilsson S. Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial. Eur Urol. 2018 Mar;73(3):427-435. doi: 10.1016/j.eururo.2017.06.021. Epub 2017 Jul 11.</citation>
    <PMID>28705540</PMID>
  </reference>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>June 20, 2019</study_first_submitted>
  <study_first_submitted_qc>September 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2019</study_first_posted>
  <last_update_submitted>September 30, 2019</last_update_submitted>
  <last_update_submitted_qc>September 30, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Policlinico Umberto I</investigator_affiliation>
    <investigator_full_name>De Vincentis Giuseppe</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>223-Radium-dicloride</keyword>
  <keyword>Radical prostatectomy</keyword>
  <keyword>overall survival</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Clinical and anagraphical data</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>starting 12 months after publication</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

